Abstract
purpose. To evaluate DNA content and cellular proliferation rates in primary and
recurrent pterygia.
methods. Matched pterygium and superior conjunctiva tissue were obtained in 36
eyes of 36 patients undergoing pterygium excision with conjunctival
autografting (24 primary pterygia, 12 recurrent pterygia). Epithelial
and fibrovascular layers were separated for analysis. Matched superior
conjunctiva obtained at the time of surgery were used as controls.
Samples were prepared according to Thompson’s method, and flow
cytometry was performed with a Becton–Dickinson FACScan. Analysis of
histograms and calculations of cell percentages in cell cycle phases
were carried out using CellFit software (version 2.0). Mean
proliferation indices (MPIs) were compared using the Wilcoxon
matched-pair signed-rank test.
results. The MPI of pterygium fibrovascular tissue (13.4) was significantly
higher than the MPI of pterygium epithelium (3.1; P =
0.0001). The MPI of pterygium fibrovascular tissue was also
significantly higher than that of superior conjunctival fibrovascular
tissue (6.0; P = 0.0001). There was no difference in
MPI values between pterygium epithelium and superior conjunctival
epithelium (3.55; P = 0.12). The MPI of fibrovascular
tissue from recurrent pterygium (73.75) was significantly higher than
the MPI of fibrovascular tissue from primary pterygium (7.3; P = 0.003).
conclusions. The finding of high levels of cellular proliferation in the
subepithelial fibrovascular layer of pterygium confirms that pterygium
is a disorder of excessive cellular proliferation and that the
fibrovascular layer is the site of cellular proliferation. Markedly
raised levels of cellular proliferation in recurrent pterygium tissue
suggest a clinical correlation between fibrovascular tissue
upregulation and pterygium recurrence after
surgery.
Pterygium is a disorder of uncertain etiology, with features
indicative of both degenerative processes and disordered growth.
Evidence of the degenerative nature of pterygium stems originally from
light microscopy findings of elastoid degeneration, which has been
linked to actinic degenerative changes from chronic ultraviolet light
exposure, and this is supported by the geographical predisposition of
pterygium to periequatorial regions, which have high levels of
ambient UV radiation.
1 2 At the same time, there are
features of the behavior of pterygium that suggest excessive or
disordered growth (i.e., tumor-like properties). Pterygium recurs
aggressively after surgical excision, and treatment modalities mimic
treatments for neoplasia, such as wide excision, adjunctive
radiotherapy, and antimitotic chemotherapy.
3 Primary
pterygia can also be locally invasive, and the pterygium epithelium has
been shown to exhibit various degrees of abnormality ranging from mild
dysplasia to carcinoma in situ.
4 The relationship of UV
radiation exposure and pterygium formation has also been compared with
the etiologic role of UV radiation exposure in Bowen’s disease and
skin malignancies.
2
Pterygium tissue consists of a superficial conjunctival epithelial
layer and an underlying fibrovascular component. We previously
determined that abnormal p53 overexpression may be present in pterygium
epithelium.
5 The abnormal expression of p53, a tumor
suppressor gene modulating expression of growth controlling genes,
which has been shown to be abnormally expressed in a wide variety of
human cancers as well as actinic skin lesions,
6 suggests
that the epithelial layer of pterygium may be involved in the
pathophysiological process of pterygium development. However, the
aggressive nature of pterygium has long been noted to be related to the
subepithelial fibrovascular component. Recurrent pterygium is almost
always thick and fleshy, and we have recently shown that the morphology
of pterygium, as determined by the degree of fibrovascular tissue
present, correlates well with recurrence rates after simple bare sclera
excision.
7 We have also shown that the surgical technique
of conjunctival rotational autografting, in which just removal of the
fibrovascular component of pterygium is performed, with replacement of
the original conjunctival epithelium overlying the pterygium, is a
successful procedure with a low rate of recurrence of
4%.
8
To further evaluate the proliferative growth process in pterygium, flow
cytometry was performed in this study to compare cellular proliferation
rates in the epithelium and fibrovascular layers of primary and
recurrent pterygia, in comparison with matched epithelial and
subepithelial layers of superior conjunctiva from these eyes.
Tissue specimens from 36 eyes with pterygium were obtained from 36
patients undergoing pterygium excision with conjunctival autografting
at the Pterygium Clinic of the Singapore National Eye Center (SNEC). Of
these, 24 were primary pterygia and 12 were recurrent pterygia. The
mean age of patients was 56 years (range, 39–81 years), with 25 men
and 11 women. The majority of patients were Chinese (29 patients,
80.6%), with 7 Malays (19.4%). The study protocol conformed to the
Declaration of Helsinki, and study protocol and informed consent form
were approved by the SNEC Ethics Committee and the SNEC Executive
Research Committee. Written informed consent was obtained from all
patients in the study.
Surgical excision of pterygia was carefully carried out to
separate epithelium from underlying fibrovascular tissue. In all
instances, it was possible to obtain fibrovascular pterygium tissue
without epithelium, but pterygium epithelium samples invariably
included a small amount of subepithelial tissue, because epithelium is
adherent to the fibrovascular layer via the substantia propria. In all
cases, matched specimens of superior bulbar conjunctiva, also separated
into epithelial and subepithelial layers, were collected at the time of
conjunctival autograft donor harvesting. Specimens were immediately
snap-frozen in liquid nitrogen and transferred to a −70°C freezer
before processing for flow cytometry analysis.
Single cell suspension was prepared using the method described by
Thompson et al.,
9 with modifications. Specimens were
dissociated in RPMI 1640 medium manually in a Petri dish. Undissociated
cells were removed by filtration through nylon mesh (40 μl). Cells
and small particles passing through the nylon mesh were collected and
centrifuged at 3000 rpm for 5 minutes. The supernatant was discarded,
and the pellet was immediately used for staining. Three hundred to 500μ
l of propidium iodine (PI) mix (containing 50 μg/ml PI,
0.01 M MgCl
2, 0.01 M Tris, 0.2% Tritron X-100,
and 1 mg/ml Rnase) was used to stain nuclear DNA in the pellet. After
sufficient mix, the staining procedure was carried out in the dark for
5 minutes before flow cytometry.
DNA flow cytometry measures the DNA content of individual cells,
which provides an accurate indication of cell cycle stage, and has been
used to analyze cell cycle kinetics in corneal epithelium after
wounding.
9 The use of flow cytometry to evaluate cell
cycle kinetics in pterygium was previously reported by Karukonda et
al.,
10 who studied 93 pterygium specimens and 19 controls
from patients in Singapore, Hong Kong, and Little Rock, Arkansas. In
that study, flow cytometry provided no evidence for increased
proliferation in pterygium tissue, compared with normal conjunctiva,
nor was there any difference in tissues between the three sites of
various geographical latitudes. In addition, specimens for recurrent
lesions were not found to be more proliferative in nature.
The present study, in contrast, showed major differences in
subepithelial fibrovascular mitotic activity between pterygium tissue
and matched superior conjunctiva, with significantly higher
proliferative rates in pterygium subepithelial fibrovascular
tissue, and the highest proliferative rates in recurrent pterygium
fibrovascular tissue. In contrast, epithelial samples did not vary
significantly in mitotic status between pterygium and superior
conjunctiva, suggesting that the major proliferative aspect of
pterygium lies in the underlying fibrovascular layer. The cellular
components of subepithelial pterygium fibrovascular tissue
comprise primarily of fibroblasts and capillary blood vessel cells,
both of which may be highly proliferative, and this study did not
distinguish exact cellular components responsible for proliferative
activity.
The use of superior bulbar conjunctiva as matched control tissue for
the present study deserves some comment. It should be noted that
environmental exposure of pterygium tissue, within the interpalpebral
fissure, must be significantly greater than that of superior bulbar
conjunctiva, and it is not surprising that prolonged sunlight or UV
light exposure and other environmental conditions (such as drying) have
been implicated in pterygium etiology.
Clinical evidence that the fibrovascular layer is important in
pterygium growth and recurrence is seen in our randomized clinical
trial comparing bare sclera excision to conjunctival
autograft.
7 In that study, pterygium morphology was graded
according to the relative degree of fibrovascular tissue present in the
body of pterygium, obscuring underlying episcleral vasculature under
slit-lamp biomicroscopic examination. Atrophic pterygia, with
translucent tissue at the pterygium body resulting in clear
visualization of underlying episcleral vessels (and hence minimal
fibrovascular tissue), were graded as T1. Thick, fleshy pterygia were
graded as the least translucent (T3), denoting complete obscuration of
episcleral vessels by the fibrovascular component, whereas all pterygia
in which partial episcleral vessel obscuration was noted were graded as
intermediate (T2). The study results showed that in bare sclera
excision, pterygium recurrence was linked to the preoperative grade,
with T3 pterygia having the highest recurrence rate, and T1 the lowest,
providing clinical evidence that the fibrovascular component of
pterygium is responsible for aggressive recurrent growth after surgery.
The proliferative nature of pterygium fibrovasculature is now borne out
in our present study. Additional supportive evidence that the
fibrovascular component is important in recurrence comes from the fact
that a low recurrence rate (4%) was encountered in our series of
conjunctival rotational autograft procedures, in which only the
fibrovascular component of the pterygium was removed, with the original
pterygium epithelium replaced.
8
The implication of our findings lies in determining new treatment
measures for pterygium removal and its recurrence. Antimitotic measures
have long been used in pterygium surgery to prevent recurrence, in the
form of the use of mitomicin C, thiotepa, and β-irradiation, which
all act to reduce the proliferative capacity of tissues at the site of
the pterygium in a nonspecific manner. Complications related to
mitomicin C or β-irradiation usually relate to an initial breakdown
in surface conjunctiva, with the development of a nonhealing epithelial
defect, which ultimately results in scleral necrosis and melting or
secondary infective scleritis and endophthalmitis. In the light of our
findings, a more focused approach to antiproliferative treatment could
be targeted at underlying fibrovascular tissue while sparing overlying
epithelial cells.
Finally, our finding of selective upregulation of pterygium fibroblast
proliferation further supports the theory that pterygium is a
proliferative growth disorder, as opposed to a simple degenerative
condition, and future therapies should focus on selective reduction in
proliferation in the fibrovascular layer of this lesion.
Supported by Singapore National Medical Research Council Grant No. NMRC/0039/1994.
Submitted for publication July 27, 1999; revised December 22, 1999; accepted January 11, 2000.
Commercial relationships policy: N.
Corresponding author: Donald Tiang–Hwee Tan, Deputy Director, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751.
[email protected] Table 1. Flow Cytometry MPIs: Epithelium Versus Fibrovascular Tissue
Table 1. Flow Cytometry MPIs: Epithelium Versus Fibrovascular Tissue
Sample | MPI | | | P Value* |
| Median | Minimum | Maximum | |
Superior conjunctival | | | | |
Epithelium | 3.55 | 0.5 | 9.1 | 0.0008 |
Fibrovascular | 6.0 | 0.4 | 48.4 | |
All pterygia | | | | |
Epithelium | 3.1 | 0.8 | 8.8 | 0.0001 |
Fibrovascular | 13.4 | 0.6 | 99.5 | |
Primary pterygia | | | | |
Epithelium | 3.2 | 1.1 | 7.4 | 0.0002 |
Fibrovascular | 7.3 | 0.6 | 99.5 | |
Recurrent pterygia | | | | |
Epithelium | 2.5 | 0.8 | 8.8 | 0.006 |
Fibrovascular | 73.75 | 2.5 | 90.5 | |
Table 2. Statistical Comparison of Flow Cytometry MPIs
Table 2. Statistical Comparison of Flow Cytometry MPIs
Sample | P Value* |
Superior conjunctival epithelium | 0.12 |
All pterygia epithelium | |
Superior conjunctival fibrovascular | 0.0001 |
All pterygia fibrovascular | |
Superior conjunctival epithelium (Primary) | 0.24 |
Primary pterygia epithelium | |
Superior conjunctival epithelium (Recurrent) | 0.34 |
Recurrent pterygia epithelium | |
Superior conjunctival fibrovascular (Primary) | 0.001 |
Primary pterygia fibrovascular | |
Superior conjunctival fibrovascular (Recurrent) | 0.0002 |
Recurrent pterygia fibrovascular | |
Superior conjunctival epithelium (Primary) | 0.66 |
Superior conjunctival epithelium (Recurrent) | |
Primary pterygia epithelium | 0.19 |
Recurrent pterygia epithelium | |
Superior conjunctival fibrovascular (Primary) | 0.13 |
Superior conjunctival fibrovascular (Recurrent) | |
Primary pterygia fibrovascular | 0.003 |
Recurrent pterygia fibrovascular | |
We thank Roger Beuerman, MD, for critical review of this
manuscript.
Dolin PJ, Johnson GJ. Solar ultraviolet radiation and ocular disease: a review of the epidemiological and experimental evidence. Ophthalmic Epidemiol
. 1994;1:155–164.
[CrossRef] [PubMed]Moran DJ, Hollows FC. Pterygium and ultraviolet radiation: a positive correlation. Br J Ophthalmol
. 1984;68:343–346.
[CrossRef] [PubMed]Sánchez–Thorin JC, Rocha G, Yelin JB. Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium. Br J Ophthalmol
. 1998;82:661–665.
[CrossRef] [PubMed]Clear AS, Chirambo MC, Hutt MSR. Solar keratosis, pterygium and squamous cell carcinoma of the conjunctiva in Malawi. Br J Ophthalmol
. 1979;63:102–109.
[CrossRef] [PubMed]Tan DTH, Lim ASM, Goh HS, Smith DR. Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium. Am J Ophthalmol
. 1997;123:404–405.
[CrossRef] [PubMed]Sim CS, Slater SD, McKee PH. Mutant p53 protein is expressed in Bowen’s Disease. Am J Dermatopathol
. 1992;14:195–199.
[CrossRef] [PubMed]Tan DTH, Chee SP, Dear KBG, Lim ASM. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol
. 1997;115:1235–1240.
[CrossRef] [PubMed]Jap A, Chan C, Lim L, Tan DTH. Conjunctival rotation autograft for pterygium. Ophthalmology
. 1999;106:67–71.
[CrossRef] [PubMed]Thompson HW, Malter JS, Steinemann TL, Beuerman RW. Flow cytometry measurements of the DNA content of corneal epithelial cells during wound healing. Invest Ophthalmol Vis Sci
. 1991;32:433–436.
[PubMed]Karukonda SRK, Thompson HW, Beuerman RW, et al. Cell cycle kinetics in pterygium at three latitudes. Br J Ophthalmol
. 1995;79:313–317.
[CrossRef] [PubMed]